KR100622716B1 - 인터루킨-12 및 허피스 심플렉스 바이러스 항원을포함하는 백신 - Google Patents

인터루킨-12 및 허피스 심플렉스 바이러스 항원을포함하는 백신 Download PDF

Info

Publication number
KR100622716B1
KR100622716B1 KR1020007008769A KR20007008769A KR100622716B1 KR 100622716 B1 KR100622716 B1 KR 100622716B1 KR 1020007008769 A KR1020007008769 A KR 1020007008769A KR 20007008769 A KR20007008769 A KR 20007008769A KR 100622716 B1 KR100622716 B1 KR 100622716B1
Authority
KR
South Korea
Prior art keywords
delete delete
herpes simplex
vaccine
interleukin
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007008769A
Other languages
English (en)
Korean (ko)
Other versions
KR20010040867A (ko
Inventor
미쉬킨에릭엠.
엘드릿지존에이치.
Original Assignee
와이어쓰 홀딩스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이어쓰 홀딩스 코포레이션 filed Critical 와이어쓰 홀딩스 코포레이션
Publication of KR20010040867A publication Critical patent/KR20010040867A/ko
Application granted granted Critical
Publication of KR100622716B1 publication Critical patent/KR100622716B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020007008769A 1998-02-12 1999-02-10 인터루킨-12 및 허피스 심플렉스 바이러스 항원을포함하는 백신 Expired - Fee Related KR100622716B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7450398P 1998-02-12 1998-02-12
US60/074,503 1998-02-12

Publications (2)

Publication Number Publication Date
KR20010040867A KR20010040867A (ko) 2001-05-15
KR100622716B1 true KR100622716B1 (ko) 2006-09-13

Family

ID=22119907

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007008769A Expired - Fee Related KR100622716B1 (ko) 1998-02-12 1999-02-10 인터루킨-12 및 허피스 심플렉스 바이러스 항원을포함하는 백신

Country Status (15)

Country Link
US (1) US6488936B1 (enExample)
EP (1) EP1053017B1 (enExample)
JP (1) JP2002502884A (enExample)
KR (1) KR100622716B1 (enExample)
CN (1) CN1224422C (enExample)
AT (1) ATE275421T1 (enExample)
AU (1) AU764036B2 (enExample)
BR (1) BR9907883A (enExample)
CA (1) CA2320041A1 (enExample)
DE (1) DE69919984T2 (enExample)
DK (1) DK1053017T3 (enExample)
ES (1) ES2226338T3 (enExample)
IL (1) IL137811A (enExample)
PT (1) PT1053017E (enExample)
WO (1) WO1999040938A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20013916A3 (cs) 1999-05-13 2002-06-12 American Cyanamid Company Adjuvantní kombinované prostředky
ATE319833T1 (de) * 1999-12-17 2006-03-15 Wyeth Corp Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
HUP0600589A2 (en) * 2000-11-10 2006-11-28 Wyeth Corp Adjuvant combination formulations
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
CN1301749C (zh) * 2005-12-09 2007-02-28 复旦大学 抗单纯疱疹病毒－2感染的多表位dna疫苗及其制备方法
US7790203B2 (en) * 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
LT2437753T (lt) 2009-06-05 2016-12-12 Infectious Disease Research Institute Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos
US8729058B2 (en) * 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
LT2850431T (lt) 2012-05-16 2018-06-25 Immune Design Corp. Vakcinos, skirtos hsv-2
KR102039520B1 (ko) 2013-04-18 2019-11-01 이뮨 디자인 코포레이션 암 치료에 이용하기 위한 gla 단일요법
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CA3023446A1 (en) 2016-05-10 2017-11-16 Hennepin Healthcare Research Institute Cytokine signaling immunomodulators and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022473A1 (en) * 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114576A0 (en) * 1994-07-22 1995-11-27 Merck & Co Inc Polynucleotide herpes virus vaccine
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022473A1 (en) * 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant

Also Published As

Publication number Publication date
KR20010040867A (ko) 2001-05-15
EP1053017A2 (en) 2000-11-22
JP2002502884A (ja) 2002-01-29
CA2320041A1 (en) 1999-08-19
WO1999040938A2 (en) 1999-08-19
IL137811A0 (en) 2001-10-31
BR9907883A (pt) 2000-11-14
AU2598199A (en) 1999-08-30
ES2226338T3 (es) 2005-03-16
PT1053017E (pt) 2004-12-31
WO1999040938A3 (en) 2000-08-24
IL137811A (en) 2005-12-18
AU764036B2 (en) 2003-08-07
EP1053017B1 (en) 2004-09-08
DK1053017T3 (da) 2004-11-22
US6488936B1 (en) 2002-12-03
CN1299287A (zh) 2001-06-13
DE69919984T2 (de) 2005-11-17
DE69919984D1 (de) 2004-10-14
CN1224422C (zh) 2005-10-26
ATE275421T1 (de) 2004-09-15

Similar Documents

Publication Publication Date Title
KR100622716B1 (ko) 인터루킨-12 및 허피스 심플렉스 바이러스 항원을포함하는 백신
Hu et al. Immunostimulating complexes (ISCOMs) for nasal vaccination
Morein et al. Current status and potential application of ISCOMs in veterinary medicine
Porgador et al. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo
ES2293700T3 (es) Tat hiv-1 o sus derivados para vacunacion terapeutica y profilactica.
CN101166559B (zh) 包含基于聚肌苷酸-聚胞苷酸的佐剂的免疫原物质
XIN et al. Intranasal administration of human immunodeficiency virus type‐1 (HIV‐1) DNA vaccine with interleukin‐2 expression plasmid enhances cell‐mediated immunity against HIV‐1
SK159294A3 (en) Vaccine composition, method of its preparation and using
Bettahi et al. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response
Villacres-Eriksson et al. IMMUNOMODULATION BYQUILLAJA SAPONARIAADJUVANT FORMULATIONS: IN VIVO STIMULATION OF INTERLEUKIN 12 AND ITS EFFECTS ON THE ANTIBODY RESPONSE
Yoo et al. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine
US9017699B2 (en) Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus
Hassan et al. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems
Dotsika et al. Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein–Barr virus Iscoms
Pertmer et al. Th1 genetic adjuvants modulate immune responses in neonates
Fernando et al. Vaccine‐induced Th1‐type responses are dominant over Th2‐type responses in the short term whereas pre‐existing Th2 responses are dominant in the longer term
KR100863367B1 (ko) 보조제 배합 제형물
Fló et al. Superiority of intramuscular route and full length glycoprotein D for DNA vaccination against herpes simplex 2. Enhancement of protection by the co-delivery of the GM-CSF gene
Richards et al. Induction of mucosal immunity against herpes simplex virus type 1 in the mouse protects against ocular infection and establishment of latency
Mohamedi et al. A comparison of oral and parenteral routes for therapeutic vaccination with HSV-2 ISCOMs in mice; cytokine profiles, antibody responses and protection
AU2005222909B2 (en) Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide
HANCOCK et al. QS-21 synergizes with recombinant interleukin-12 to create a potent adjuvant formulation for the fusion protein of respiratory syncytial virus
Pacheco et al. Intranasal immunization with HIV reverse transcriptase: effect of dose in the induction of helper T cell type 1 and 2 immunity
Tirabassi et al. A mucosal vaccination approach for herpes simplex virus type 2
McGhee et al. Mucosal Th1-versus Th2-type responses for antibody-or cell-mediated immunity to simian immunodeficiency virus in rhesus macaques

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090905

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090905

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000